Valuation: Nektar Therapeutics

Market Cap 2.46B 2.13B 1.99B 1.83B 3.46B 234B 3.5B 23.46B 9.17B 117B 9.23B 9.03B 387B P/E 2026 *
-8.07x
P/E 2027 * -6.71x
Enterprise Value 2.46B 2.13B 1.99B 1.83B 3.46B 234B 3.5B 23.46B 9.17B 117B 9.23B 9.03B 387B EV / Sales 2026 *
59.3x
EV / Sales 2027 * 66.5x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+3.07%
1 week+2.81%
Current month+2.96%
1 month+2.42%
3 months-16.26%
6 months+93.30%
Current year+72.09%
1 week 67.11
Extreme 67.11
73.09
1 month 64.24
Extreme 64.24
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.6
Extreme 21.6
109
3 years 6.19
Extreme 6.188996
109
5 years 6.19
Extreme 6.188996
290.55
10 years 6.19
Extreme 6.188996
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
7/24/26 A Free

Chief Technology Officer

16,500 0.0488%
7/24/26 A Free

Chief Executive Officer

57,200 0.1693%
6/30/26 A Sell

Chief Technology Officer

-5,681 0.0168%
Change 5-day change 1-year change 3-year change Capi.($)
+3.07%+2.81%+212.68%+810.75% 2.46B
+10.00%+14.90%+53.89%+87.07% 62.53B
+1.37%-5.70%+23.89%+62.65% 52.43B
-0.98%-1.19%-16.98%-14.21% 23.1B
+0.30%-5.17%-11.23%+349.07% 21.4B
+0.61%-1.57%+32.81%-25.80% 17.76B
+4.29%+8.97%+200.03%+341.85% 15.47B
+2.28%-1.09%+13.67%+613.33% 14.68B
+1.71%-0.90%+52.13%+176.27% 14.08B
+4.16%+4.44%+444.12%+183.06% 12.62B
Average +2.72%+1.17%+100.50%+258.40% 23.65B
Weighted average by Cap. +3.65%+1.84%+62.27%+154.27%

Financials

2026 *2027 *
Net sales 41.44M 35.99M 33.55M 30.82M 58.29M 3.94B 58.93M 396M 155M 1.97B 156M 152M 6.53B 36.99M 32.12M 29.94M 27.51M 52.03M 3.52B 52.6M 353M 138M 1.76B 139M 136M 5.83B
Net income -249M -216M -202M -185M -350M -23.7B -354M -2.38B -930M -11.85B -936M -915M -39.26B -351M -305M -284M -261M -493M -33.37B -499M -3.35B -1.31B -16.68B -1.32B -1.29B -55.27B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
04/08/26 $72.76 +3.07% 717,950
03/08/26 $70.59 -0.11% 611,868
31/07/26 $70.67 -1.09% 497,236
30/07/26 $71.45 +1.09% 676,759
29/07/26 $70.68 -0.13% 982,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
72.76USD
Average target price
153.22USD
Spread / Average Target
+110.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock